Overview

Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery

Status:
Completed
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
The aim of the study is to show that first line treatment with concentrated fibrinogen has superiority over the conventional therapy with fresh frozen plasma (FFP), platelets, and cryoprecipitate in perioperative management of bleeding after complex cardiac surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Nova Scotia Health Authority